Malgorzata Ostrowska
Overview
Explore the profile of Malgorzata Ostrowska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pawlik K, Ostrowska M, Gumienna-Kontecka E
Inorg Chem
. 2025 Mar;
PMID: 40067133
Pathogenic bacteria and all other species require Mn(II) and Fe(II) ions for proper growth. Microbes use a variety of assimilation pathways to obtain the necessary metal ions, and their metal...
2.
Orzel B, Ostrowska M, Potocki S, Zoroddu M, Kozlowski H, Peana M, et al.
Inorg Chem
. 2025 Mar;
PMID: 40048504
Often necessary for efficient Fe(II) trafficking into bacterial cell, the Feo system is a vital transporter for many pathogenic bacteria and indispensable for proper development and survival in the host...
3.
Kubica J, Adamski P, Gajda R, Kubica A, Ostrowska M, Casu G, et al.
Cardiol J
. 2025 Jan;
32(1):83-89.
PMID: 39776051
According to the ESC guidelines, cangrelor may be considered in P2Y12-inhibitor-naïve acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). The aim of this review is to summarize available...
4.
Kubica J, Adamski P, Ostrowska M, Kubica A, Gajda R, Badariene J, et al.
Int J Cardiol
. 2024 Dec;
421():132897.
PMID: 39647786
De-escalation of dual antiplatelet (DAPT) intensity may be considered in patients with high risk of bleeding after acute coronary syndrome. Some high risk patients after de-escalation may require antithrombotic therapy...
5.
Ostrowska M, Nowosad K, Mikoluc B, Szczerba H, Komon-Janczara E
Nutrients
. 2024 Nov;
16(22).
PMID: 39599702
Background: Phenylketonuria (PKU) is a metabolic disorder that necessitates dietary restrictions, potentially impacting the composition of gut and oral microbiota. This study aimed to compare the microbiota composition between children...
6.
Ostrowska M, Kasprzak M, Fabiszak T, Gajda J, Jaje-Rykowska N, Michalski P, et al.
PLoS One
. 2024 Oct;
19(10):e0309922.
PMID: 39436870
Background: Patients hospitalized due to Coronavirus disease 2019 (COVID-19) are still burdened with high risk of death. The aim of this study was to create a risk score predicting in-hospital...
7.
Ostrowska M, Kasprzak M, Stolarek W, Grzelakowska K, Krys J, Kubica A, et al.
Rev Cardiovasc Med
. 2024 Jul;
23(9):292.
PMID: 39077718
Background: The coronavirus disease-2019 (COVID-19) pandemic is surging across Poland, leading to many direct deaths and underestimated collateral damage. We aimed to compare the influence of the COVID-19 pandemic on...
8.
Ostrowska M, Komon-Janczara E, Vogt A, Glibowski P
Ann Agric Environ Med
. 2023 Dec;
30(4):779-782.
PMID: 38153085
Phenylketonuria (PKU) is a metabolic and genetic disorder caused by a phenylalanine hydroxylase (PAH) gene deficiency that raises Phe levels in organs. Dietary therapy involves an elimination diet and Phe-free...
9.
Kubica J, Adamski P, Dobrzycki S, Gajda R, Gasior M, Gierlotka M, et al.
Cardiol J
. 2023 Nov;
31(1):133-146.
PMID: 37964649
Cangrelor is the only intravenous P2Y12 receptor antagonist. It is an adenosine triphosphate analog that selectively, directly, and reversibly binds to the platelet P2Y12 receptors exerting its antiaggregatory effect. Cangrelor...
10.
Orzel B, Pelucelli A, Ostrowska M, Potocki S, Kozlowski H, Peana M, et al.
Inorg Chem
. 2023 Nov;
62(45):18607-18624.
PMID: 37910812
The interactions between two peptide ligands [AcCCAASTTGDCH () and AcRRARSRVDIELLATRKSVSSCCAASTTGDCH ()] derived from the cytoplasmic C-terminal region of FeoB protein and Fe(II), Mn(II), and Zn(II) ions were investigated. The Feo...